While there are already several drugs already approved to treat hyperphosphatemia in patients with chronic kidney disease ...

Hyperphosphatemia is a condition that means you have high levels of phosphorus in your body. It can happen due to your diet or a change in your kidneys’ function. Often, hyperphosphatemia has no ...

DUBAI, United Arab Emirates, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Future Market Insights estimates that the Hyperphosphatemia Market will experience a rapid expansion between the years 2023 and 2033. By ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription The kidneys, in addition to removing toxins, ...

Given the suboptimal outcomes with existing therapies to manage chronic kidney disease patients on dialysis, there is a substantial unmet need that additional treatment options could potentially ...

Please provide your email address to receive an email when new articles are posted on . “So, what can we do beyond binders?” he asked during the presentation. One method is to increase the frequency ...

Phosphorus is increased in most patients undergoing dialysis, and phosphorus control usually requires dietary restrictions and the use of several phosphate binder pills. Binders must be taken with ...

Tenapanor, a novel agent that has been submitted to the US Food and Drug Administration (FDA) for approval for the treatment of hyperphosphatemia in patients undergoing dialysis, moved a step closer ...

A research team from Argentina prospectively studied the frequency of hyperphosphatemia following the administration of oral sodium phosphate (OSP) in low-risk patients. They found that the standard ...